Alimera Sciences, Inc. (ALIM)
| Market Cap | 183.24M |
| Revenue (ttm) | 80.75M |
| Net Income (ttm) | -21.39M |
| Shares Out | 52.35M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | 117.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,885 |
| Open | 3.570 |
| Previous Close | 3.630 |
| Day's Range | 3.280 - 3.655 |
| 52-Week Range | 1.560 - 4.380 |
| Beta | 1.20 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+121.61%) |
| Earnings Date | May 13, 2024 |
About ALIM
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the... [Read more]
Full Company ProfileFinancial Performance
In 2023, ALIM's revenue was $80.75 million, an increase of 49.19% compared to the previous year's $54.13 million. Losses were -$21.39 million, 18.1% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ALIM stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 121.61% from the latest price.
News
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy Protocol AL is studying ILUVIEN or faricimab (...
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macu...
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians...
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians...
Alimera Appoints Maggie A. Pax to Its Board of Directors
ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners con...
Alimera Sciences Reports Third Quarter 2023 Results
ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners co...
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners con...
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners co...
Alimera Sciences Reports Second Quarter 2023 Results
ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners co...
Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update
ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners conce...
Alimera Acquires U.S. Commercial Rights to YUTIQ®
ATLANTA, May 18, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concer...
Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET
ATLANTA, May 17, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concer...
Alimera Sciences Reports First Quarter 2023 Results
ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners conc...
Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update
ATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concer...
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries
Horus to increase ILUVIEN commercial presence with Nordic Retinal Specialists Horus to increase ILUVIEN commercial presence with Nordic Retinal Specialists
Alimera Sciences Announces 2022 Financial Results and Business Update
• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update
Conference Call to be held Friday, March 31, at 9:00am Eastern Time Conference Call to be held Friday, March 31, at 9:00am Eastern Time
Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®
Switzerland is latest market for Alimera in continued geographic expansion Switzerland is latest market for Alimera in continued geographic expansion
Alimera Sciences Announces Third Quarter 2022 Financial Results
ATLANTA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners co...
Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments
Data from the Phase 4 observational real-world safety study of the intravitreal implant were presented at the annual American Academy of Ophthalmology (AAO) conference. Data from the Phase 4 observati...
Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network
ILUVIEN or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy ILUVIEN or faricimab (6.0 mg) injections versus observ...
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland
Reimbursement granted with no restrictions to the label Reimbursement granted with no restrictions to the label
Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress
Positive findings from the RIVER study and data on retreatment with ILUVIEN available Positive findings from the RIVER study and data on retreatment with ILUVIEN available
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners con...